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Abstract
In this study, we present the design considerations of a device to assist in the potential treatment of hemorrhagic stroke
with the aim of stopping blood from flowing out into brain tissue. We present and model three designs for the clinical
scenarios when saccular aneurysms rupture in the middle cerebral artery in the brain. We evaluate and model these
three designs using computer aided design software, SolidWorks, which allows the devices to be tested using finite ele-
ment analysis and also enables us to justify that the materials chosen were suitable for potential use. Computational fluid
dynamics modelling were used to demonstrate and analyse the flow of blood through the artery under conditions of
normal and ruptured states. We conclude that our device could potentially be useful in the treatment of hemorrhagic
stroke, and the modelling process is useful in assisting in determining the performance of our devices.
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Introduction
According to the World Health Organization, 15mil-
lion people suffer from strokes worldwide per annum
and of these 6.2million people die and 5million people
are left with permanent disability. Stroke is the leading
cause of death for people above the age of 60 years and
constitutes the fifth leading cause in people aged 15–
59 years. In the UK alone, there are more than 100,000
strokes and 38,000 deaths as a result of stroke each
year.1,2 Hemorrhagic strokes account for about 15% of
all strokes3 and arises when a blood vessel in or around
the brain ruptures.4–7 Weaknesses may occur within the
vessels of the brain giving rise to aneurysms. There are
several approaches to the treatment of aneurysms7–10 at
the pre-rupture stage, which include coiling of the
aneurysm. However, if left untreated an aneurysm may
rupture resulting in hemorrhagic stroke. There are two
types of hemorrhagic strokes: (1) an intracerebral hae-
morrhage (ICH) and (2) subarachnoid haemorrhage
(SAH) (and it is known that hemorrhagic strokes tend
to arise more so in hypertensive patients).11 In hemor-
rhagic stroke, blood leaks into the brain at high pres-
sure, and causes damage to surrounding tissues and
cerebral structures. Escaping free flowing blood not
only brings about damage to the brain cells but also
causes an increase in intracranial pressure (ICP). This
results in a lack of oxygen and nutrients reaching the
brain cells. Consequently, the affected cells die. The
sudden build of pressure can lead to unconsciousness
or death.12 Therefore, devices are needed to prevent the
flow of blood out of the artery/vessel to stop the leak-
age of blood into brain tissue. Statistics reveal that
between 30% and 60% of people who suffer ICH will
die.13,14 Of the 25% of people who survive an ICH,
some will experience major improvement in their symp-
toms. However, about 50% will suffer from long-term
neurological problems.15 Other treatments aim to
decrease the risk of more bleeding and manage blood
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pressure so that enough blood will still flow to allow
perfusion of the brain. A range of medications may be
given that assist in controlling the ICP. These include
dexamethasone and mannitol.16 A major factor in
determining the outcome of an ICH rests with control-
ling the ICP Normal ICP is around 20mmHg. Another
means of controlling ICP is by removal of cerebrosp-
inal fluid (CSF) from the ventricles. That is facilitated
by placing a ventricular catheter (VP shunt) into the
ventricles to drain CSF, thus allowing room for the
hematoma (that may eventually form) to expand with-
out damaging the brain.17 Other treatments for larger
hematomas situated deep inside the brain include
stereotactic aspiration. This procedure involves the
attachment of a stereotactic frame with computed
tomography (CT) scans to evacuate the blood clot
(hematoma).18 Craniotomy is also used in the treatment
of hemorrhagic stroke. This procedure involves cutting
a hole in the skull with a drill to expose the brain and
removal of the blood.18
A SAH occurs when a blood vessel ruptures outside
the brain and bleeding arises in the subarachnoid space.
About 5% of all strokes fall into this category.12 The
subarachnoid space is filled with CSF. Consequently,
when blood flows from a ruptured vessel into the subar-
achnoid space it creates an increase in the volume of
fluid in the subarachnoid space. This in turn gives rise to
an increase in the pressure inside the skull and over the
brain. The increased pressure may then press the brain
against the bony skull or cause the brain to shift-a so-
called ‘mass effect’ and then herniate. Associated
obstruction of the normal CSF flow can bring about
enlargement of the ventricles, called hydrocephalus
(build-up of fluid in the brain), giving rise to confusion,
lethargy and loss of consciousness in the patient.19,20
Vasospasm is also a common complication which may
occur 5–10days after a SAH. This occurs when blood
by-products cause irritation of the wall of the artery
causing it to contract and spasm. This vasospasm can
cause narrowing of the artery lumen which becomes
decreased in diameter, which in turn reduces blood flow
still further to that area. This can give rise to a second-
ary stroke.19 Approximately half of patients who suffer
SAH will survive, however many of these will suffer with
a disability and the remaining half of cases are fatal.20
It is clear to see that the main cause of arteries/blood
vessels rupture in the brain is due to high blood pres-
sure forming aneurysms. For brain aneurysms treat-
ment surgical clipping is a very common and effective
procedure.21 The aim of clipping is to place a small
metallic clip along the neck of the aneurysm. This will
prevent blood from entering the aneurysm sac so that it
no longer poses a risk of bleeding. In addition, several
devices currently in use for treating cerebral aneurysms
include coiling methods, flow catheters and biodegrad-
able stents.
There are potential risks involving endovascular coil-
ing, such as injury/damage to the artery or the aneurysm
itself and potential rupture of the aneurysm.
Furthermore, vasospasm of the artery itself may occur
leading to an abrupt narrowing of the artery, resulting
in decreased blood flow to the part of the brain being
supplied by that artery. A study22 involving the stent
assisted coiling of intracranial aneurysms involved 508
cases. They concluded that stent-assisted coiling of
intracranial aneurysms was safe, and effective and gave
rise to durable aneurysm closure. However, they further
concluded that there appeared to be greater rates of
complication when ruptured aneurysms were involved.
Long-term success of endovascular coiling to treat
aneurysms is about 80%–85%, aneurysm recurrence
after coiling occurs in 34% of patients.23 Recurrence
occurs due to coils not completely blocking off the
aneurysm or if the coils become compact within the
aneurysm. Over 10% of patients will undergo a second
treatment to place additional coils, usually within the
first year. All patients who have had coiling as treat-
ment for an aneurysm are advised to return after 6, 12
and 24months for a diagnostic angiogram to monitor
for residual or recurring aneurysm. Due to the high cost
of coiling and the potential occurrence of recurrence, it
is evident that there is a market for a more cost-effective
and better performing method for treating ruptured
aneurysms in the brain.
Flow diverters can potentially suffer from branch
occlusion and aneurysm recurrence. Consequently,
these stents are often used for unruptured aneurysms.24
Bioresorbable polymeric stents25 are also used. Such
biodegradable stents can release substances which
include anti-inflammatory drugs to control intimal
hyperplasia that can arise on account of the interven-
tional procedure itself. However, such polymeric
resorbable stents need to provide adequate strength
(together with ease of insertion, etc) for the vessel over
a desired period of time.
Aims and objectives
We aim to design and produce a prototype device that
could potentially be inserted into a haemorrhaging vessel
in the brain. The aim of this device is to ‘plug the gap’ in
the ruptured section to stop blood flowing out of the
ruptured vessel into the brain causing further damage.
To be effective, our device must satisfy a number of
requirements; the device must be made of biocompatible
material and be quick to deploy in surgery. The device
must conform to the ‘Standard ISO-10993’26‘Biological
Evaluation of Medical Devices’; the materials from
which it is made must be corrosion resistant; the device
must also ideally be visible on X-ray visualisation and
radiographic filming techniques such as computed tomo-
graphy angiography (CTA) scan, for the surgeon to view
the deployment of the device during and after surgery;
the device must be effective in stopping the bleeding in
the artery, capable of remaining in situ post deployment,
and able to stay in the brain for the duration of the
patient’s lifetime; the device must not impede the natural
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flow of blood through the artery; the device must fit
individual vessels; the device must also withstand the
effects of vasospasm; the design must be ‘leak-proof’
and not allow blood to seep through out of the aneur-
ysm rupture and into the brain.
From the Design Specifications, we have come up
with a few suitable designs of self-expanding Nitinol
stent with expanded polytetrafluoroethylene (ePTFE)
graft, and the following studies illustrate the modelling
of the devices and their expected mechanical perfor-
mance while being implemented.
The designs were undertaken using SolidWorks, using
the feature ‘sheet metal’. All designs were 8mm in length
and 3mm in diameter with wall thickness 0.2mm.
Computer-aided design modelling
The steps in the design are shown in Figure 1(a)–(f). A
hollow tube with an inner diameter of 2.6mm, outer
diameter of 3mm and 8mm height was modelled. The
tube was then cut two-thirds along its length. A ‘sheet
metal’ was created from the remaining one-third tube
and flattened using the ‘flatten-bends’ tool (Figure
1(c)). Once the flat sheet was obtained, the geometry of
the stent could be created as a pattern (step 3). The flat
sheet was then curved back into the one-third tubing.
Finally, from the one-third part assembly the three sep-
arate parts were then joined together to form the full
stent.
Our three designs are shown in Figures 2–4.
The main features of the design are tabulated in
Table 1.
A key feature of the design concerns how to attach
the ePTFE graft to the Nitinol stent. The material cho-
sen was ultra-high molecular weighted braided poly-
ethylene (UHMWPE). It was chosen due to its
strength, durability, its properties involving knot tying
and polyester core which was designed to enhance knot
Figure 1. Sheet metal: (a) step 1, (b) step 2, (c) step 3, (d) step 4, (e) step 5 and (f) sheet metal-finished assembly, step 6.
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security.27,28 Another feature that the stent device
might have is anchoring pins (Figure 5). Anchoring
pins are used to anchor the stent into the artery wall,
so the flow of blood does not dislodge the anchoring
pins, or if any vasospasm occurs, the device will not be
dislodged from its position. The anchoring pin will
anchor itself into the tunica intima of the artery wall.
Design calculations and finite element
analysis modelling
Clearly the choice of materials to be used is very impor-
tant29–31 to demonstrate that the chosen materials
(Nitinol and ePTFE) for the device could withstand the
forces/pressures exerted on them after deployment. In
the artery, the minimum thickness of the stent and
ePTFE graft was calculated. This calculation together
with the hemodynamic calculations are shown in
Appendix 1. Blood travelling through arteries/blood
vessels exerts a hoop stress against the vessel’s walls.
This same force would therefore be exerted against the
device inserted into a ruptured blood vessel. These
equations were used to determine the parameters
related to haemodynamic flow and forces: since failure
would occur when the hoop stress exceeded the ulti-
mate tensile strength (UTS) of the material, the UTS
was used instead of the hoop stress to calculate the
minimum thickness needed. The results are summarised
in Table 2.
A value of 0.2mm was chosen for the stent thickness
and the ePTFE graft thickness was chosen to be
0.0508mm taking into account a safety factor; ePTFE
graft diameter: 3.0508mm; stent diameter: 3mm. To
evaluate the stent design, ANSYS workbench 15 was
used for finite element analysis (FEA) together with
computational fluid dynamics (CFD). The testing
involved validating the design and to see if the materials
chosen could withstand the conditions inside an artery
(a)
1
(b)
(c)
Figure 2. Design 1: (a) side view, (b) angle view and (c) stent
and graft material.
(a)
(b)
(c)
Figure 3. Design 2: (a) side view, (b) angle view and (c) stent
and graft material.
(a)
(b)
(c)
Figure 4. Design 3: (a) side view, (b) angle view and (c) stent
and graft material.
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and the behaviour of the material. Since ANSYS work-
bench 1532 did not have the materials Nitinol and
ePTFE in its database, these were added into the data-
base manually using the material properties from
Tables 3 and 4. In the FEA, the pressure being applied
to the structure and graft material was the mean arterial
pressure during hypertensive crisis as this would mimic
the conditions in which the stent would be facing after
deployment. The mean arterial pressure was doubled
from 133 to 266mmHg when testing to prove the
device could withstand even the worst-case scenario.
Our FEA designs are shown in Figures 6–8.
FEA results overview
Table 5 shows an overview of the results of the FEA,
the Von Mises stress of all the designs were compared
against the yield strength of Nitinol and ePTFE: yield
strength (Nitinol) – 1000MPa; yield strength (ePTFE)
– 21,700MPa.
It can be seen from the FEA testing (Table 5) that
design 1 (closed cell, ‘S’ connector) performed the best
and design 2 (open cell, straight line connector) per-
formed the worst of the three designs. Taking into
account the yield strength of Nitinol and ePTFE it can
be seen that designs 1 and 3 were under a tenth of the
yield strength of Nitinol while design 2 was just over a
Table 1. Overview of the designs.
Design 1 Design 2 Design 3
Material Electro-polished Nitinol Electro-polished Nitinol Electro-polished Nitinol
Form Tubing Tubing Tubing
Fabrication Laser cut Laser cut Laser cut
Geometry Closed cell Open cell Closed cell
Additions Tantalum radiopaque
markers ePTFE graft
Tantalum radiopaque
markers ePTFE graft
Tantalum radiopaque
markers ePTFE graft
Method of deployment Self-expanding Self-expanding Self-expanding
ePTFE: expanded polytetrafluoroethylene.
Figure 5. Schematic view of the anchoring pin.
Table 2. Minimum thicknesses of stent and graft material.
Material Minimum thickness (mm)
Nitinol 7.373 1026
ePTFE 5.89633 1024
ePTFE: expanded polytetrafluoroethylene.
Table 3. Nitinol material properties added into ANSYS
workbench 15.
Property Value Units
Nitinol
Density 6450 kg/m3
Young’s modulus 90,000 MPa
Poisson’s ratio 0.3[68]
Tensile yield strength 1000 MPa
Tensile ultimate strength 1400 MPa
Super elasticity
Sigma SAS 52,000[68] MPa
Sigma FAS 60,000[68] MPa
Sigma SSA 30,000[68] MPa
Sigma FSA 20,000[68] MPa
Epsilon 0.063[68] mm21
Alpha 0.09[68]
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tenth. When the ePTFE graft was added for the analy-
sis, the Von Mises stress of all three designs dropped
significantly and were now 3.4% of the yield strength
of Nitinol and 0.15% of the yield strength of ePTFE
(Table 6). This analysis showed that changes could be
made to the thickness of the stent structure and ePTFE
graft material, that is, that they both could be
decreased, which would save a substantial amount of
cost during the manufacturing process.
CFD analysis
To perform CFD analysis, consideration was given to
the fact that blood is a non-Newtonian fluid with pul-
satile flow. The equations used were the continuity and
Navier-stokes equations.
Continuity equation
∂p
∂t
+r  rVð Þ=0 ð1Þ
However, as blood can be regarded as an incompres-
sible fluid, the rate of density change is zero, thus the
continuity equation can be simplified to the following
form
r  V=0 ð2Þ
Navier–Stokes equation
r
dV
dt
+ v  rv
 
= rp+mr2v+ f ð3Þ
Figure 6. FEA design 1 stent: (a) structural analysis and (b) graft analysis.
Figure 7. FEA design 2 stent: (a) structural analysis and (b) graft analysis.
Table 4. ePTFE material properties added into ANSYS
workbench 15.
ePTFE
Property Value Units
Density 2200 kg/m3
Young’s modulus 552 MPa
Poisson’s ratio 0.3
Tensile yield strength 21,700 MPa
Tensile ultimate strength 34,500 MPa
ePTFE: expanded polytetrafluoroethylene.
6 Proc IMechE Part H: J Engineering in Medicine 00(0)
The viscosity coefficient of m is not a constant but
rather a function of shear rate, blood gets less viscous
as the shear rate increases. So, here the blood viscosity
will be modelled using the Carreau fluid model, which
can be seen as
meff _gð Þ=minf+ m0  minf
 
1+ l _gð Þ2
 n1
2 ð4Þ
where meff is effective viscosity, and m0, minf, l and n
are material coefficients. For the case of blood,
m0 =0.056 kg/m s; minf =0.0035 kg/m s; l=3.313 s;
n=0.3568. Carreau fluid model is appropriate for
blood flow simulation, as in large arteries the blood
has Newtonian behaviour with high shear rate flow,
whereas in smaller arteries blood flow is non-
Newtonian with low shear rates, and Carreau fluid
model can accommodate this variation through the
index n.33
Boundary conditions
Inlet. Mammalian blood flow is both pulsatile and cyc-
lic in nature, hence the velocity at the inlet will not be a
constant but instead has a time varying periodic profile.
The pulsatile profile within each period is considered to
be a combination of two phases, systolic and diastolic.
This pulsatile profile is shown in Figure 9. During the
systolic phase, the velocity inlet varies in a sinusoidal
pattern, the sine wave during the systolic phase has a
peak velocity of 0.5m/s and a minimum velocity of
0.1m/s. So, if we assume a heartbeat rate of 120/min,
the duration of each period will be 0.5 s. This is the
time analysed for the transient flow.
Figure 8. FEA design 3 stent: (a) structural analysis and (b) graft analysis.
Table 5. FEA results overview.
Maximum (MPa) Minimum (MPa)
Design 1 (closed cell, ‘S’ connector)
Stent structure 74.39 0.000085
Stent and graft 23.91 0.000017
Design 2 (open cell, straight line connector)
Stent structure 118.80 0.000135
Stent and graft 33.45 0.000018
Design 3 (closed cell, tube connector)
Stent structure 105.50 0.38824
Stent and graft 28.75 0.04495
FEA: finite element analysis.
Table 6. Summary of FEA results.
Summary of FEA results
Highest Von Mises stress on stent structure Design 2
Lowest Von Mises stress on stent structure Design 1
Highest Von Mises stress on stent and graft Design 2
Lowest Von Mises stress on stent and graft Design 1
FEA: finite element analysis.
Figure 9. The blood flow pulsatile profile.
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Outlet. The outlet was set using the mean arterial pres-
sure of someone in a hypertensive crisis which is
133.3mmHg. However, for the purpose of our analy-
sis, a higher value of 180mmHg was used which equa-
ted to 23,994Pa. The CFD analysis undertaken aimed
to show how blood flows through (1) a ‘normal middle
cerebral artery’, (2) ‘middle cerebral artery with a fusi-
form aneurysm’ and (3) ‘middle cerebral artery with a
saccular aneurysm’ and with the latter two, ruptures of
aneurysms in these arteries, respectively.
Middle cerebral artery‘no aneurysm’
simulation
The ‘no aneurysm’ condition (i.e. normal artery) was
first considered in order to show the analysis underta-
ken would match what theoretically happens in a nor-
mal blood vessel, theory states that ‘blood flow velocity
is faster in the middle of the artery and slowest at the
vessel wall’.34
Figure 10(b) and (c) demonstrates that the velocity
of blood flow is faster in the centre of the artery as the
velocity is 1.85e21 compared to at the walls where it is
4.62e22. These figures show that the inlet pressure is
24,030 which is higher than outlet pressure which was
set at the boundary conditions, this shows the pressure
of flow entering the middle cerebral artery (MCA) is
lower than what is leaving.
MCA fusiform aneurysm
Figure 11(b) shows how the flow disperses into the fusi-
form aneurysm and no longer stays linear as it would in
a normal MCA.
Figure 11(c) shows the total pressure through a
MCA fusiform aneurysm, it can be seen that as the
blood travels through the artery and flows against the
walls of the fusiform aneurysm the pressure is higher
than the outlet.
MCA fusiform ruptured
Figure 12(b) shows a rupture in the fusiform aneurysm,
it can be seen that due to the rupture the flow velocity
dramatically decreases and some of the flow, flows out
of the artery. This flow leaving the artery is the blood
which will go into the brain and cause damage/compli-
cations as discussed earlier in the background research.
Figure 12(c) shows the total pressure through a MCA
fusiform ruptured.
MCA saccular aneurysm
Figure 13(b) shows the velocity of flow through the
MCA saccular aneurysm and it can be seen during a
saccular aneurysm that the flow increases as it leaves
the MCA.
Figure 13(c) shows the pressure through a MCA sac-
cular aneurysm and it can be seen that there is a pres-
sure of 2.401e4 Pa going into the saccular aneurysm.
MCA saccular aneurysm ruptured
simulation
Since 80%–90% of all aneurysms are of the saccular
type, we used CFD analysis undertaken aimed to show
how blood flows through middle cerebral artery saccu-
lar aneurysm ruptured. The inlet boundary was set as a
velocity-inlet and the rupture and outlet boundary were
set as pressure-outlet.
Figure 14(b) shows the velocity through an MCA
saccular aneurysm ruptured. It can be seen that as the
flow reaches the ‘sac’ of the aneurysm which is at the
base of the aneurysm, the velocity increases quite sig-
nificantly and flows out. The blood consequently leaves
the aneurysm and passes into the brain where it can
cause damage/complications to brain tissue.
MCA saccular aneurysm ruptured with
device simulation
CFD analysis has been used to show how design 1
(design which performed the best during FEA) would
stop blood flow from a ruptured saccular aneurysm
since it is the most common type. The inlet boundary
was set as a velocity-inlet and the rupture and outlet
boundary were set as pressure-outlet.
Figure 10. (a) Middle cerebral artery, (b) velocity through MCA no aneurysm and (c) total pressure through the MCA no
aneurysm.
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Figure 11. (a) MCA fusiform aneurysm, (b) velocity through MCA fusiform aneurysm and (c) total pressure through MCA fusiform
aneurysm.
Figure 12. (a) MCA fusiform ruptured, (b) velocity through MCA fusiform ruptured and (c) pressure through MCA fusiform
ruptured.
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Figure 15(a) shows the ePTFE graft in a ruptured
aneurysm. It can be clearly seen that with the inserted
graft material the flow is blocked from going into the
rupture and into the brain. This analysis is central to
showing that the proposed device can function for its
intended purpose.
Discussion and conclusion
In our study, we investigated three designs for use in
arteries in the brain that are commonly involved in hae-
morrhagic strokes, for example, the MCA. We pre-
sented the results of modelling the capacity of these
Figure 13. (a) MCA saccular aneurysm, (b) velocity through MCA saccular aneurysm and (c) pressure through MCA saccular
aneurysm.
Figure 14. (a) Saccular aneurysm ruptured and (b) velocity through MCA ruptured saccular aneurysm.
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devices to prevent blood flowing out from the arterial
rupture of saccular aneurysms. FEA was carried out on
all three designs which validated that the materials cho-
sen for the devices were fit for purpose and would not
fail under the worst case scenario (double of the mean
arterial pressure during hypertensive crisis). CFD test-
ing was carried out to see what the different type of
flow was like in a normal middle cerebral artery
(MCA), MCA with a fusiform aneurysm, MCA with a
saccular aneurysm and when a saccular aneurysm rup-
tured. Then after rupture of a saccular aneurysm the
device was shown to stop the flow from leaving the
MCA at the rupture, effectively ‘plugging the gap’.
An ePTFE graft appeared to be successful blocking
blood flow out of an artery in a ruptured aneurysm. It
would appear therefore that at least in principle this
type of material would potentially be useful in arresting
the flow of blood out of a ruptured artery in haemor-
rhagic stroke. However, we note that further research
would need to be undertaken to investigate the biocom-
patibility issues associated with the ultimate choice of
material.
Such modelling enables us to predict the perfor-
mance of the devices without having to build several
prototypes, thus enabling a given device to be opti-
mised prior to prototype manufacture taking place, this
saving on costs.
For the new device to be successful it has to meet
vital requirements: be easily inserted into the blood ves-
sel/artery; deployed quickly and efficiently to minimise
blood loss into the brain; bio-compatible so it won’t be
rejected by the patient; excellent mechanical properties
to stop it failing under the pressure of blood flow. The
proposed self-expanding stent can potentially satisfy
these requirements. Comparing to balloon-expanding
(BX) method, self-expanding (SX) stents can be more
suited for the device. The main reasons are that they
can adapt their shape to the vessel wall, become a part
of the anatomy and act in harmony with native vessels
and support the vessel wall. Radial compliance of an
SX stented vessel is much greater than that of a typical
BX stented vessel. Axial stiffness, which is directly
reflected in bending compliance, is also different, with
SX stents being again much more compliant than BX
stents of identical design; this applies both in delivery
and deployment. Self-expanding stents have no strength
limitation and elastically recover even after complete
flattening or radial crushing. Which makes them the
ideal choose for when vasospasm occurs as they won’t
resist the narrowing and increase the size of rupture/
damage to the artery.
Nitinol material’s super elasticity was best suited
since Nitinol alloys are the only stent material which
follows the same elastic deformation behaviour of the
structural materials of the living body.35 ePTFE was
chosen due to its superior density and elongation val-
ues. These materials will facilitate the deployment of
the stent.
Hooks are commonly used in arterial stents. It is
important however to consider blood flow velocity and
blood pressure in particular artery in the brain at spe-
cific anatomical site. This would be the subject of fur-
ther investigation in abattoir and cadaveric specimens
with practical flow dynamics added including radial
forces in intracranial arteries in conjunction with a
range of anatomical variants. This would yield infor-
mation on whether use of a hook would be an asset.
Out of the three designs proposed, the FEA model-
ling results indicate that device number 1 had the best
performance. As the device has been modelled on
SolidWorks, the next step would involve the manufac-
turing of a prototype device, so that testing procedures
can be carried out to validate its performance in respect
to factors such as longitudinal compression, radial
compression, 3-point bending, and torsion. Based on
such measurements, the performance of the device can
then be fine-tuned and optimised for potential use in
haemorrhagic stroke treatment. Such CFD modelling
Figure 15. (a) Design 1 in situ in a ruptured MCA saccular aneurysm and (b) velocity through graft material of the ruptured MCA
saccular aneurysm.
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is useful in predicting the performance of the device
under given conditions in particular vessels in the
brain, for example, the results in Figure 15 of model-
ling an ePTFE graft indicated the successful blocking
of blood flow in a ruptured aneurysm. Our results also
showed that choice of material, thickness and elasticity
are important factors in the design process and that
these also should be biocompatible. Although we
recognise that computational modelling has limitations
and is no ultimate substitute for physical testing, never-
theless the type of modelling we have undertaken is a
useful adjunct in the design and testing of the perfor-
mance of such devices.
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Appendix 1
Haemodynamic calculations
Mean arterial pressure
MAP=
1
3
SBPð Þ+ 2
3
DBPð Þ
MAP=
1
3
180ð Þ+ 2
3
110ð Þ
MAP=133:3mmHg
Pressure=133:33133:3
Pressure=17, 768:89Pa
Force=pressure3surface area
Force=17, 768:8932pr(r+L)
Force=17768:8931:577933104
Force=2:80N
where
DBP=diastolic blood pressure (mmHg)
SBP=systolic blood pressure (mmHg)
MAP=mean arterial pressure (mmHg)
1mmHg=133:3 Pa
Resistance to flow
SVR=
83L3h
p3r4
SVR=
8316343106
p31:444
SVR=3:793105 kg=mm4 s
SVR=3:793105kg=mm4 s3 10
9
60
SVR=631:6mmHgmin=mL
where
r=radius (mm)
L=length (mm)
SVR=resistance
h=viscosity(kg=mms)
Turbulence
Re=
r3v3d
h
Re=
1:063106333032:88
43106
Re=251:856
where
Re=Reynolds number
r=density (kg/mm3)
n=velocity (mm/s)
d=diameter (mm)
h=viscosity (kg/mms)
Wall tension
Wall tension=
P3r
t
Wall tension=
0:0177688931:44
0:51
Wall tension=0:05017N=mm2
where
P=blood pressure (mmHg)
t=wall thickness (mm)
r=radius (mm)
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Cardiac output
CO=
MAP
SVR
CO=
133:3
631:6
CO=0:211mL=min
MAP=mean arterial pressure
SVR=system vascular resistance
Hoop stress
Wall tension=
P3D
23t
Wall tension=
0:0177688932:88
230:51
Wall tension=0:05017N=mm2
where
P=pressure
D=diameter
t=wall thickness of vessel
Calculation of the minimum thickness
needed
ePTFE
ePTFE stress=
pressure3diameter
23thickness
Thickness=
pressure3diameter
23ePTFE stress
Thickness=
13331:333104
2345
Minimum thickness=5:89633104 mm
Nitinol
Nitinol stress=
pressure3diameter
23thickness
Thickness=
Pressure3 diameter
23 ePTFE Nitinol
Thickness=
13331:333104
231200
Minimum thickness=7:373106 mm
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